Применение рилизинг-системы «Мирена®» в профилактике и лечении гиперплазии эндометрия у женщин с метаболическим синдромом. (Взгляд эндокринолога)

1. Внутриматочная контрацепция. Под ред. В.Н.Прилепской. М.: Медпресс, 2000.
2. Affandi B, Suherman SK et al. Serum lipid in Norplant implant user: a cross-sectional study. Contraception 1987; 36: 429–34.
3. Andersson K, Stadberg E, Mattsson LA, Rybo G et al. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women – effects on lipid during 12 months of treatment. Int J Fertil Menopausal Stud 1996; 41 (5): 476–83.
4. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. J Am Med Assoc 1991; 265: 1861–7.
5. Buchen H, Villard-Mackintosh L, Vessey M et al. Epidemiology of pelvic inflammatory disease in parous women with special reference to intrauterine device use. Br J Obstet Gynaecol 1990; 97: 780–8.
6. Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: result from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 6: 1102–9.
7. Chi I, Farr G. The non-contraceptive effects of the levonorgestrel-releasing intrauterine device. Adv Contracep 1994; 10: 271–85.
8. Coleman M, McCowan L, Farquhar C. The levonorgestrel-releasing intrauterine device: a wider role than contraception. Aust NZ J Obstet Gynecol 1997; 37 (2): 195–201.
9. Crosignani PG, Vercellini P, Mosconi P et al. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997; 90 (2): 257–63.
10. Diaz J, Faundes A, Diaz M, Marchi N. Evaluation of the clinical performance of a levonorgestrel-releasing IUD, up to seven years of use, in Campinas, Brazil. Contraception 1993; 47: 169–75.
11. Fahraeus L, Larsson-Cohn U, Wollentin L. L-norgestrel and progesterone have different influences on plasma lipoproteins. Eur J Clin Invest 1983; 13: 447–53.
12. Farley TMM, Rosenberg M, Rowe PJ et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339: 785–8.
13. Faundes A, Alvarez F, Brach V et al. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anaemi during fertility regulation. Int J Gynaecol Obstet 1988; 26: 429–33.
14. Faundes A, Alvarez F, Diaz J A. Latin American experience with levonorgestrel IUD. Ann Med 1993; 25: 149–53.
15. Jonsson B, Landgren BM, Eneroth P. Effects of various IUDs on the composition of cervical mucus. Contraception 1991; 43: 447–58.
16. Luukkainen T. Levonorgestrel-releasing intrauterine device. In: Frontiers in human reproduction. Seppala M, Hamberger L (Eds.) New York The New York Academy of Sciences, 1991; 43–9.
17. Nilsson CS, Lahteenmaki PLA, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fert Steril 1984; 41 (1): 52–5.
18. Ortiz ME, Croxatto H. Mode of action of IUDs Contraception 1987; 36: 37–53.
19. Porkka KV, Erkkola R, Taimela S, Raitakari OT et al. Influence of oral contraceptive use on lipoprotein and other coronary heart disease risk factors. Ann Med 1995; 27 (2): 193–8.
20. Robinson GE, Bounds W, Kubba AA et al. Functional ovarian cysts associated with levonorgestrel-releasing intrauterine device. Br J Fam Plann 1989; 14: 131–2.
21. Silveberg SG, Haukkamaa M, Arko H et al. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol 1986; 5 (3): 235–41.
22. Singer A, Ikomi A. Successful treatment of uterine fibroids using an intrauterine progesterone device. Int J Gynecol Obstet 1994; 46 (Suppl. 2): 55.
23. Singh K, Ratnam SS. A study on the effects of Norplant implantable contraceptive on lipid, lipoprotein, and apolipoprotein metabolism in Singaporean women. Contraception 1997; 56: 77–83.
24. Sivin I, Schmidt F Effectiveness of IUDs: A review. Contraception 1987; 36: 55–84.
25. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 mg/d and copper Tcu 380 Ag intrauterine contracepnive divice: a multicenter study. International Covvittee for Contraception Research (ICCR). Fertil Steril 1994; 6 (1): 70–1.
26. Sivin I, Stern J, Coutinho E et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20. Contraception 1991; 44: 473–80.
27. Suherman SK, Affandi B, Korver T. The effects of implanon on lipid metabolism in comparison with Norplant. Contraception 1999; 60 (5): 281–7.
28. Wilson S, Marley C. A comparative study of users of Norplant in England and Indonesia. Br J Fam Plann 1995; 21 (3): 98–101.

О.Р.Григорян, Е.Н.Андреева

ФГУ Эндокринологический научный центр